Altogether, these genetic alterations influence clinical decisions for metastatic disease management with BRAF and MEK inhibitor treatment being suitable for patients with BRAF-mutated melanomas, while patients with KIT-mutated melanomas benefit from KIT inhibitors [7]. This evidence concerns the gene BRAF and metastatic neoplasm.